We thank Dr Chipps and his colleagues for their comments pointing to the differences between the recommendations made in the Diagnosis and Management of Rhinitis Practice Parameter (DMRPP) and the updated Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, particularly related to the use of intranasal H1-antihistamines. A second letter by Dr Spector and colleagues, some of whom authored the former letter, raises, in our view, similar issues. Our responses address the points made in both letters.

doi.org/10.1016/j.jaci.2011.01.069, hdl.handle.net/1765/33430
Journal of Allergy and Clinical Immunology
Erasmus MC: University Medical Center Rotterdam

Brozek, J., Bousquet, J., Baena-Cagnani, C., Bonini, S., Canonica, W., Casale, T., … Zuberbier, T. (2011). Reply [to letters from Dr. Chipps and Dr. Spector]. Journal of Allergy and Clinical Immunology, 127(6), 1643–1645. doi:10.1016/j.jaci.2011.01.069